Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Business Overview and Strategic Developments
CRL logo

Charles River Laboratories Navigates $384 Million Impairment Amid Biopharma Spending Slowdown

CRL10-KFiling Date: 2/18/2026
Charles River Laboratories International, Inc.
Description

What this story covers

Charles River Laboratories reported $4.02 billion in 2025 revenue, navigating a transitional year marked by $384 million in impairment charges and NHP supply challenges. Despite a net loss, resilient cash flows and aggressive restructuring signal a strategic pivot.

Story snapshot

CompanyCharles River Laboratories International, Inc.
TickerCRL
VariantStandard detailed
Duration12:46
Filing type10-K
PeriodAnnual 2025
IndustryHealthcare & Pharmaceuticals
Accession0001100682-26-000022
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing10-KView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in